| Medical Policy |
Revision |
|
Bone Marrow Transplant for Neuroectodermal Tumors and Ependymoma
|
Specialty Matched Consultant Advisory Panel review 11/13/2008. Added statement to the "When Not Covered" section indicating; "3. Multiple-cycle high-dose chemotherapy (with or without associated radiotherapy) and autologous stem-cell support (i.e., tandem transplants) is investigational in all patients with medullobastoma, other PNETs or the CNS, or ependymoma." "Policy Guidelines" section updated. References added. Notice given 12/22/08. Policy effective 3/30/2009.
|
|
Bone Marrow Transplant for Non Hodgkin’s Lymphomas
|
Specialty Matched Consultant Advisory Panel review 11/13/08. Removed reference to "intermediate" lymphoma in #1. under the "When covered" section. Added wording to "1.b. To consolidate a first complete remission (for patients with diffuse large B-cell lymphoma, only those with an age-adjusted International Prognostic Index ( IPI) score that predicts a high- or high-intermediate risk of relapse)". Removed the statement in #2, "and for marginal zone lymphoma with indolent behavior or lymphoma or lymphoplasmatoid lymphoma". Under the "When not covered" section removed wording in 1.b "intermediate or high grade" and replaced it with "aggressive". Added "1.d. For peripheral T-cell lymphoma (PTCL) at any stage of disease." References added. Notice given 12/22/08. Effective date 3/30/09.
|
|
Bone Marrow Transplant for Primary Amyloidosis or Waldenstrom’s Macroglobulinemia
|
Specialty Matched Consultant Advisory Panel review 11/13/2008. Added "2. High-dose chemotherapy with allogeneic stem-cell support is considered investigational to treat primary systemic amyloidosis." to the "When not covered" section. Updated rationale in the "Policy Guidelines" section. Notice given 12/22/08. Effective date 3/30/09. References added.
|
|
Bone Marrow Transplant for Solid Tumors of Childhood
|
Specialty Matched Consultant Advisory Panel review 11/13/2008 . Changed wording in #3 in the "When Covered" section from "poor" risk to "high" risk. Added #5 to the "When Not Covered" section to indicate; "Multiple cycle high-dose chemotherapy and hematopoietic stem cell support (i.e., tandem or multiple transplants) is considered investigational for the treatment of neuroblastoma." Updated "Policy Guideline" section. References added. Notice given 12/22/08. Effective date 3/30/09.
|
